190 related articles for article (PubMed ID: 24777899)
1. Predicting the parasite killing effect of artemisinin combination therapy in a murine malaria model.
Patel K; Batty KT; Moore BR; Gibbons PL; Kirkpatrick CM
J Antimicrob Chemother; 2014 Aug; 69(8):2155-63. PubMed ID: 24777899
[TBL] [Abstract][Full Text] [Related]
2. Mechanism-based model of parasite growth and dihydroartemisinin pharmacodynamics in murine malaria.
Patel K; Batty KT; Moore BR; Gibbons PL; Bulitta JB; Kirkpatrick CM
Antimicrob Agents Chemother; 2013 Jan; 57(1):508-16. PubMed ID: 23147722
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of piperaquine in a murine malaria model.
Moore BR; Batty KT; Andrzejewski C; Jago JD; Page-Sharp M; Ilett KF
Antimicrob Agents Chemother; 2008 Jan; 52(1):306-11. PubMed ID: 17984231
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated falciparum malaria.
Rijken MJ; McGready R; Phyo AP; Lindegardh N; Tarning J; Laochan N; Than HH; Mu O; Win AK; Singhasivanon P; White N; Nosten F
Antimicrob Agents Chemother; 2011 Dec; 55(12):5500-6. PubMed ID: 21947392
[TBL] [Abstract][Full Text] [Related]
5. Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial.
West African Network for Clinical Trials of Antimalarial Drugs (WANECAM)
Lancet; 2018 Apr; 391(10128):1378-1390. PubMed ID: 29606364
[TBL] [Abstract][Full Text] [Related]
6. Semimechanistic Pharmacokinetic and Pharmacodynamic Modeling of Piperaquine in a Volunteer Infection Study with Plasmodium falciparum Blood-Stage Malaria.
Wattanakul T; Baker M; Mohrle J; McWhinney B; Hoglund RM; McCarthy JS; Tarning J
Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33468477
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of two versus three-day regimens of dihydroartemisinin-piperaquine for uncomplicated malaria in military personnel in northern Cambodia: an open-label randomized trial.
Lon C; Manning JE; Vanachayangkul P; So M; Sea D; Se Y; Gosi P; Lanteri C; Chaorattanakawee S; Sriwichai S; Chann S; Kuntawunginn W; Buathong N; Nou S; Walsh DS; Tyner SD; Juliano JJ; Lin J; Spring M; Bethell D; Kaewkungwal J; Tang D; Chuor CM; Satharath P; Saunders D
PLoS One; 2014; 9(3):e93138. PubMed ID: 24667662
[TBL] [Abstract][Full Text] [Related]
8. Development of a pharmacodynamic model of murine malaria and antimalarial treatment with dihydroartemisinin.
Gibbons PL; Batty KT; Barrett PH; Davis TM; Ilett KF
Int J Parasitol; 2007 Dec; 37(14):1569-76. PubMed ID: 17585920
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of dihydroartemisinin/piperaquine and artesunate monotherapy for the treatment of uncomplicated Plasmodium falciparum malaria in Central Vietnam.
Rovira-Vallbona E; Van Hong N; Kattenberg JH; Huan RM; Hien NTT; Ngoc NTH; Guetens P; Hieu NL; Mai TT; Duong NTT; Duong TT; Phuc BQ; Xa NX; Erhart A; Rosanas-Urgell A
J Antimicrob Chemother; 2020 Aug; 75(8):2272-2281. PubMed ID: 32437557
[TBL] [Abstract][Full Text] [Related]
10. Dihydroartemisinin-piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study.
Spring MD; Lin JT; Manning JE; Vanachayangkul P; Somethy S; Bun R; Se Y; Chann S; Ittiverakul M; Sia-ngam P; Kuntawunginn W; Arsanok M; Buathong N; Chaorattanakawee S; Gosi P; Ta-aksorn W; Chanarat N; Sundrakes S; Kong N; Heng TK; Nou S; Teja-isavadharm P; Pichyangkul S; Phann ST; Balasubramanian S; Juliano JJ; Meshnick SR; Chour CM; Prom S; Lanteri CA; Lon C; Saunders DL
Lancet Infect Dis; 2015 Jun; 15(6):683-91. PubMed ID: 25877962
[TBL] [Abstract][Full Text] [Related]
11. Piperaquine pharmacodynamics and parasite viability in a murine malaria model.
Moore BR; Ilett KF; Page-Sharp M; Jago JD; Batty KT
Antimicrob Agents Chemother; 2009 Jul; 53(7):2707-13. PubMed ID: 19380600
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and ex vivo pharmacodynamic antimalarial activity of dihydroartemisinin-piperaquine in patients with uncomplicated falciparum malaria in Vietnam.
Nguyen DV; Nguyen QP; Nguyen ND; Le TT; Nguyen TD; Dinh DN; Nguyen TX; Bui D; Chavchich M; Edstein MD
Antimicrob Agents Chemother; 2009 Aug; 53(8):3534-7. PubMed ID: 19528277
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand.
Tarning J; Ashley EA; Lindegardh N; Stepniewska K; Phaiphun L; Day NP; McGready R; Ashton M; Nosten F; White NJ
Antimicrob Agents Chemother; 2008 Mar; 52(3):1052-61. PubMed ID: 18180343
[TBL] [Abstract][Full Text] [Related]
14. Modeling Prevention of Malaria and Selection of Drug Resistance with Different Dosing Schedules of Dihydroartemisinin-Piperaquine Preventive Therapy during Pregnancy in Uganda.
Wallender E; Zhang N; Conrad M; Kakuru A; Muhindo M; Tumwebaze P; Kajubi R; Mota D; Legac J; Jagannathan P; Havlir D; Kamya M; Dorsey G; Aweeka F; Rosenthal PJ; Savic RM
Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30530597
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic Interactions between Tafenoquine and Dihydroartemisinin-Piperaquine or Artemether-Lumefantrine in Healthy Adult Subjects.
Green JA; Mohamed K; Goyal N; Bouhired S; Hussaini A; Jones SW; Koh GC; Kostov I; Taylor M; Wolstenholm A; Duparc S
Antimicrob Agents Chemother; 2016 Dec; 60(12):7321-7332. PubMed ID: 27697758
[TBL] [Abstract][Full Text] [Related]
16. Piperaquine concentration and malaria treatment outcomes in Ugandan children treated for severe malaria with intravenous Artesunate or quinine plus Dihydroartemisinin-Piperaquine.
Byakika-Kibwika P; Ssenyonga R; Lamorde M; Blessborn D; Tarning J
BMC Infect Dis; 2019 Dec; 19(1):1025. PubMed ID: 31795967
[TBL] [Abstract][Full Text] [Related]
17. Plasmodium berghei: parasite clearance after treatment with dihydroartemisinin in an asplenic murine malaria model.
Moore BR; Jago JD; Batty KT
Exp Parasitol; 2008 Apr; 118(4):458-67. PubMed ID: 18023429
[TBL] [Abstract][Full Text] [Related]
18. Population Pharmacokinetics of Piperaquine in Young Ugandan Children Treated With Dihydroartemisinin-Piperaquine for Uncomplicated Malaria.
Sambol NC; Yan L; Creek DJ; McCormack SA; Arinaitwe E; Bigira V; Wanzira H; Kakuru A; Tappero JW; Lindegardh N; Tarning J; Nosten F; Aweeka FT; Parikh S
Clin Pharmacol Ther; 2015 Jul; 98(1):87-95. PubMed ID: 25732044
[TBL] [Abstract][Full Text] [Related]
19. Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial.
Tran TH; Dolecek C; Pham PM; Nguyen TD; Nguyen TT; Le HT; Dong TH; Tran TT; Stepniewska K; White NJ; Farrar J
Lancet; 2004 Jan; 363(9402):18-22. PubMed ID: 14723988
[TBL] [Abstract][Full Text] [Related]
20. Metabolism of Piperaquine to Its Antiplasmodial Metabolites and Their Pharmacokinetic Profiles in Healthy Volunteers.
Liu H; Zhou H; Cai T; Yang A; Zang M; Xing J
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29784841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
